Frequency generally decreased as participants remained on a stable retatrutide dose over time
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon (GCG) receptor This triple G mechanism targets multiple pathways for appetite control, insulin sensitivity, glucose regulation, and energy/fat metabolismpotentially offering greater effects than dual (GLP-1/GIP) or single agonists
3 The takeaway: Behavior change matters to people on GLP-1s, and the Noom app continues to be associated with stronger real-world GLP-1 outcomes Taken together, these findings tell a clear story: people who pair GLP-1 medication with consistent engagement in the Noom app see more success at weight loss, and, independently, they stay with the program longer
Mirror checks and photographs feel unchanged despite significant objective loss
Phase 3 trials test the candidate in larger populations and provide much of the evidence used in regulatory review
This biochemical evidence strongly supports that Retatrutide not only suppresses inflammation transcriptionally but also actively restores lipid mediator balance, contributing to immune resolution
